A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

Part of paid clinical trials in Anaheim, California.

Sponsor
AbbVie
Study ID
NCT07291232
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • ABBV-295 — DRUG
    Subcutaneous Injections
  • Placebo — DRUG
    Subcutaneous Injections

Study Details

This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.

Key Dates

Start date
Nov 19, 2025
Status verified
May 2026
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
48 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: ABBV-295 or Placebo-Group 1
    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
  • Experimental: ABBV-295 or Placebo-Group 2
    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
  • Experimental: ABBV-295 or Placebo-Group 3
    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.
  • Experimental: ABBV-295 or Placebo-Group 4
    Participants will receive subcutaneous doses of ABBV-295 or Placebo for 13 weeks.

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to approximately 145 days ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
CenExel ACT- Anaheim Clinical Trials /ID# 283200AnaheimCalifornia92801-
Acpru /Id# 278624GrayslakeIllinois60030-

Find similar trials in Anaheim, CA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
CenExel ACT- Anaheim Clinical Trials· Anaheim, CAAcpru· Grayslake, IL

Related Studies